Sphera Funds Management LTD. Invests $3.72 Million in enGene Holdings Inc. (NASDAQ:ENGN)

Sphera Funds Management LTD. acquired a new stake in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 560,000 shares of the company's stock, valued at approximately $3,724,000. Sphera Funds Management LTD. owned 1.27% of enGene at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vontobel Holding Ltd. purchased a new position in enGene during the fourth quarter worth about $69,000. Jane Street Group LLC acquired a new position in shares of enGene in the 4th quarter worth approximately $93,000. Cubist Systematic Strategies LLC boosted its position in shares of enGene by 15.7% during the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock worth $102,000 after purchasing an additional 2,080 shares during the period. Corton Capital Inc. purchased a new position in shares of enGene during the 4th quarter worth approximately $157,000. Finally, Orbimed Advisors LLC acquired a new stake in enGene in the 4th quarter valued at approximately $6,120,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Price Performance

NASDAQ:ENGN traded down $0.12 during mid-day trading on Wednesday, hitting $4.08. 59,225 shares of the company's stock traded hands, compared to its average volume of 131,567. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The company has a market cap of $207.99 million, a PE ratio of -7.07 and a beta of -0.36. The firm's 50 day simple moving average is $4.13 and its 200 day simple moving average is $6.01. enGene Holdings Inc. has a 1 year low of $2.65 and a 1 year high of $13.28.

Analyst Ratings Changes

ENGN has been the topic of a number of research reports. Morgan Stanley decreased their price target on enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 11th. UBS Group lowered enGene from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $34.00 to $7.00 in a research note on Friday, February 14th. Piper Sandler began coverage on enGene in a research report on Tuesday, February 18th. They issued an "overweight" rating and a $26.00 price target on the stock. JMP Securities restated a "market outperform" rating and issued a $18.00 price target on shares of enGene in a research note on Tuesday, April 29th. Finally, HC Wainwright restated a "buy" rating and set a $25.00 price target on shares of enGene in a research note on Tuesday, March 11th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $23.29.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.